Arcturus Therapeutics vs Viridian Therapeutics, Inc.\DE
ARCT and VRDN side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How ARCT and VRDN compare
Viridian Therapeutics, Inc.\DE is the larger company, worth 15 times as much as Arcturus Therapeutics ($3.5B against $238M).
Viridian Therapeutics, Inc.\DE grew revenue faster over the last twelve months (−62.8% versus −68.7% for Arcturus Therapeutics).
Arcturus Therapeutics keeps more of each dollar of sales as profit, with a net margin of −286% compared with −1724% at Viridian Therapeutics, Inc.\DE.
Arcturus Therapeutics scores higher on the StockData Score (9 against 3 for Viridian Therapeutics, Inc.\DE), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | ARCT | VRDN |
|---|---|---|
| Size and price | ||
| Market cap | $238M | $3.5B |
| Share price | $8.36 | $30.87 |
| Change, 1 year | 2.8% | 6.7% |
| Change, 5 years | −77.1% | 58.7% |
| Beta (5Y) | 2.16 | 0.80 |
| Employees | 111 | 252 |
| StockData Score | ||
| Total score | 9 (better) | 3 |
| Valuation score | 2 (better) | 0 |
| Growth score | 0 | 1 (better) |
| Performance score | 2 (better) | 1 |
| Health score | 5 (better) | 1 |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/S | 7.8× (better) | 133× |
| P/B | 1.4× (better) | 6.0× |
| FCF yield | −26.3% | −9.8% (better) |
| Fair value | $8.63 | – |
| Margin of safety | 3.1% | – |
| Growth | ||
| Revenue growth (TTM) | −68.7% | −62.8% (better) |
| Revenue growth, 5Y average | 53.8% | 132% (better) |
| Profitability | ||
| Operating margin | −311% (better) | −1781% |
| Net margin | −286% (better) | −1724% |
| FCF margin | −205% (better) | −1305% |
| Return on equity | −44.4% (better) | −83.7% |
| Return on invested capital | −534% | – |
| Financial health | ||
| Debt / equity | 0.00 | – |
| Interest coverage | – | −19.3× |
| Current ratio | 6.68 | 14.46 (better) |
| Altman Z-score | −1.08 | 2.03 (better) |
| Piotroski F-score | 2 | 4 (better) |
| Dividends and buybacks | ||
| Buyback yield | – | −1.4% |
| Shareholder yield | 0.00% (better) | −1.4% |
| Ownership | ||
| Held by institutions | 87.9% | 120% |
| Held by insiders | 8.1% | 21.8% |
| Insider net buying, 12 months | – | $19.6M |
| Short interest, % of float | 20.7% | 19.2% |
Go deeper
- ARCT stock overview
- ARCT income statement
- ARCT valuation and score
- VRDN stock overview
- VRDN income statement
- VRDN valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.